Head and Neck Oncology

Annals of Surgical Oncology

, Volume 16, Issue 2, pp 240-245

First online:

Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma

  • Xiaolong LeeAffiliated withDepartment of Thyroid & Neck, Tianjin Medical University Cancer Hospital
  • , Ming GaoAffiliated withDepartment of Thyroid & Neck, Tianjin Medical University Cancer Hospital Email author 
  • , Yifeng JiAffiliated withDepartment of Thyroid & Neck, Tianjin Medical University Cancer Hospital
  • , Yang YuAffiliated withDepartment of Thyroid & Neck, Tianjin Medical University Cancer Hospital
  • , Ying FengAffiliated withDepartment of Thyroid & Neck, Tianjin Medical University Cancer Hospital
  • , Yigong LiAffiliated withDepartment of Thyroid & Neck, Tianjin Medical University Cancer Hospital
  • , Yan ZhangAffiliated withDepartment of Thyroid & Neck, Tianjin Medical University Cancer Hospital
  • , Wenyuan ChengAffiliated withDepartment of Thyroid & Neck, Tianjin Medical University Cancer Hospital
  • , Wenchuan ZhaoAffiliated withDepartment of Thyroid & Neck, Tianjin Medical University Cancer Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Papillary thyroid cancers often occur as microcarcinoma. Some papillary thyroid microcarcinoma (PTMC) have been considered to be high aggressive according to advanced disease stages, extrathyroidal extension, and severe cervical lymph node metastasis. Although several factors are thought to predict the occurrence of aggressiveness from PTMCs, the origin of aggressiveness has been rarely studied. To answer this question, the correlation between BRAFV600E mutation and high aggressive PTMCs was investigated. The clinicopathological characteristic of totally 64 cases of PTMCs was investigated and the BRAFV600E mutational status of them was identified. BRAFV600E mutation was exclusively detected in PTMCs (37.5%). The data provided no correlation between the occurrence of BRAFV600E mutations and clinicopathological parameters, such as sex, age, and tumor-like lesions combination. The prevalence of BRAFV600E mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (< 0.05) than that of PTMCs without aggressive behavior. The BRAFV600E mutated PTMCs exhibited signs of higher aggressiveness than PTMCs without the mutation. BRAFV600E mutation may be a marker of high aggressiveness in PTMCs.